Epstein-Barr Virus (EBV) Nuclear Antigen (EBNA) Antibody, IgG
The Epstein-Barr virus (EBV) is a member of the herpes virus family, and is responsible for many disorders including infectious mononucleosis and other lymphoproliferative disorders. In young adults, EBV infection may be clinically manifested as infectious mononucleosis with typical symptoms of sore throat, fever, and lymphadenopathy. Following primary EBV infection, the virus establishes its latency in B lymphocytes that may extend through life. Reactivation of EBV infection or enhanced EBV activation has been documented in immunodeficient or immunosuppressed patients, i.e., organ transplant patients, individuals with malignancies, in HIV infected patients, pregnant women, and persons of advanced age. EBV has also been associated in the pathogenesis of two human cancers: Burkitt’s lymphoma and nasopharyngeal carcinoma. Several reports have suggested that EBV infection is associated with chronic fatigue syndrome.
Epstein Barr nuclear antigen (EBNA) antibody begins to appear in the third or fourth week from onset of disease but is uniformly present by 6 months and lasts indefinitely. Therefore, EBNA is positive in most cases of past or late stage (convalescent) EBV infections, and it might not be reactive in cases of acute infection. The EBNA test may be used to confirm previous infection, or to monitor treatment of a current infection.
- Confirm previous EBV infection
- Monitor treatment of current EBV infection
- As an aid in diagnosis of infectious mononucleosis
- As an aid in diagnosis of Burkitt's lymphoma
- As an aid in diagnosis of nasopharyngeal carcinoma
- As an aid in diagnosis of chronic fatigue syndrome
Positive in:
- Infectious mononucleosis
- Previous EBV infection
- Burkitt’s lymphoma (almost all African cases, about 20% of non-African cases)
- Nasopharyngeal carcinoma (virtually all cases)
- Lymphoproliferative disorders (some)
Negative in:
- Usually negative in intital/early acute infection
<0.9 Index value (No detectable IgG antibody to EBNA
0.91 - 1.09 Index value (Equivocal results, testing should be repeated in 1-2 weeks)
>1.10 index value (Reactive for IgG antibody to EBNA
Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA).
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 60 days
- Virus Res. 2002 Jan 30;82(1-2):109-13. [PMID: 11885937]
- Am Fam Physician. 2004;70:1279. [PMID: 15508538]
- Annu Rev Pathol. 2006;1:375-404. [PMID: 18039120]
- Lancet Infect Dis. 2003 Mar;3(3):131-40. [PMID: 12614729]
- Am J Med. 2007 Oct;120(10):911.e1-8. [PMID: 17904463]
- In Vivo. 2007 Sep-Oct;21(5):707-13. [PMID: 18019402]
- Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8. [PMID: 11298158]
- Stevens, Christine Dorresteyn. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company. 2010.EBV early antigen (EA) ELISA II package insert. Wampole Laboratories ref. 425000CE 06/2005